Current News
Dec 15, 2015
Med BioGene licensee to begin GeneFX logistics in Q1
September 10, 2015
Med BioGene - Background on GeneFx® Lung Commercialization
August 21, 2015
Med Biogene Reports Financial Results for Q2 2015
June 21, 2015
From activist to CEO, how Iain Weir Jones landed the top job at Med Bio-Gene
June 1, 2015
MedBiogene Provides Update
May 29, 2015
Med Biogene Reports Financial Results for Q1 2015
May 21, 2015
Med BioGene Issues Revised Fact Sheet
May 21, 2015
Med BioGene Engages IR Company
April 29, 2015
Med Biogene Reports Financial Results for 2014
April 9, 2015
Additional International Exposure for MBI’s commercialization Partner
March 26, 2015
Neil Campbell, the CEO of Helomics®, Message on Cancer Video
March 26, 2015
First 10 Industry Partners Announced
March 26, 2015
Helomics - 100,000 Genomes Project
March 3, 2015
Appointment Of New Director
February 16, 2015
MBI Closes Shares For Debt Transaction
February 3, 2015
Med BioGene Provide Shareholders Update
January 13, 2015
MBI Announces Shares For Debt Transaction
November 30, 2014
Med Biogene Reports Financial Result for Q3 2014
October 02, 2014
Status Update Precision Therapeutics Inc. to Med Biogene Inc.
October 01, 2014
Closing of Private Placement
September 05, 2014
Directors Nominated By Dissident Shareholder Elected At Annual General Meeting
September 04, 2014
Med BioGene Announces Receipt of Proxies for Upcoming Annual and Special Meeting
August 29, 2014
Med BioGene Reports Financial Results for Q2 2014
August 21, 2014
Med BioGene Responds to Assertions Made by Dissident Shareholder
August 15, 2014
Med BioGene Provides Update and Announces Proposed Financing
August 06, 2014
Med BioGene Announces Director Nominations and Postponement of Annual and Special Meeting
March 24, 2014
Med BioGene Announces Regulatory Approval of GeneFx® Lung
|
Med BioGene licensee to begin GeneFX logistics in Q1
Ticker Symbol: C:MBI
Med BioGene licensee to begin GeneFX logistics in Q1
Med BioGene Inc (C:MBI)
Shares Issued 86,578,353
Last Close 12/10/2015 $0.05
Tuesday December 15 2015 - News Release
Mr. Iain Weir-Jones reports
MED BIOGENE INC. ANNOUNCES COMMERCIALIZATION STATUS OF GENEFX LUNG
Med BioGene Inc. has confirmed that its licensee, Helomics, has advised the company that logistical procedures necessary for the first commercial application of GeneFX Lung will commence in the first quarter of 2016.
MBI and Helomics(TM) have been in frequent and active discussions over the past several months as Helomics(TM) continued to move towards the commercialization of MBI's GeneFX Lungtrademark diagnostic test. As reported earlier in the year, a variety of go-to-market strategies are being pursued concurrently, with the expectation that a diversified approach will yield faster and larger overall returns. Shareholders should be confident that MBI's approach of minimizing overhead and the personal investments by management and the Directors, are indicative of the Company's overall confidence in its prospects.
During Q1 2016 Helomics(TM) will implement the logistical steps necessary to enable the first health care provider to commence shipping biopsy specimens to the Helomics(TM) CLIA approved laboratory in Pittsburgh. The first commercial test specimens are expected to be available for analysis in Pittsburgh in Q2 2016. This will constitute the initial phase of commercialization as defined in the April 2011 Commercialization Agreement between MBI and Precision Therapeutics, Helomics(TM) predecessor.
In addition to this commercial pre-market access agreement Helomics(TM) anticipates announcing that a second major US health care provider has approved the use of the GeneFX Lungtrademark diagnostic test for its members. The logistical requirements for the commencement of commercial testing for this provider will start in Q2 2016.
For reasons of commercial confidentiality the specific details of the Helomics(TM) agreements relating to the adoption of the GeneFX Lungtrademark test will not be released until the pre-launch period via press release by Helomics. Given the success of Helomics(TM) diligent marketing activities of the GeneFX Lungtrademark test in a difficult regulatory climate, we hope that the milestones announced previously will be reached before the end of 2016.
We wish all our shareholders a healthy, happy, and prosperous New Year; and thank them for their support over the last sixteen months.
We seek Safe Harbor.
© 2015 Canjex Publishing Ltd. |
Quick Facts
Download our facts sheet
|